DrugPatentWatch Database Preview
Nextwave Company Profile
What is the competitive landscape for NEXTWAVE, and what generic alternatives to NEXTWAVE drugs are available?
NEXTWAVE has two approved drugs.
There are twelve US patents protecting NEXTWAVE drugs.
There are thirty-four patent family members on NEXTWAVE drugs in fourteen countries.
Summary for Nextwave
| International Patents: | 34 |
| US Patents: | 12 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Nextwave
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-002 | Dec 4, 2015 | RX | Yes | No | 9,295,642 | Start Trial | Y | Start Trial | |||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | 8,287,903 | Start Trial | Y | Start Trial | |||
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 8,062,667 | Start Trial | Y | Start Trial | |||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | 9,844,544 | Start Trial | Y | Start Trial | |||
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 8,465,765 | Start Trial | Y | Start Trial | |||
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 8,563,033 | Start Trial | Y | Start Trial | |||
| Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | 9,295,642 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for NEXTWAVE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Oral Suspension | 5 mg/mL | ➤ Subscribe | 2013-08-02 |
International Patents for Nextwave Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2428205 | Start Trial |
| Denmark | 2428205 | Start Trial |
| China | 101400343 | Start Trial |
| Israel | 236847 | Start Trial |
| Austria | 536867 | Start Trial |
| Brazil | PI0709606 | Start Trial |
| Spain | 2721900 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
